eligibility_summary
Adults (≥18) with untreated classical HL: stage III/IV or bulky II, measurable FDG‑avid lesion ≥1.5 cm, ECOG 0–1, adequate marrow, renal, hepatic function, consent and contraception/pregnancy test. Exclude: NLPHL, recent other cancers, prior checkpoint or brentuximab, or recent chemo/RT, active CNS/PML, serious infection, ILD/pulmonary or neuro disease, major cardiac or Child‑Pugh B/C, ≥G2 neuropathy, HBV/HCV/HIV, pregnancy/breastfeeding, autoimmunity/immunosuppression, prior transplant, planned RT/other therapy, recent live vaccine, hypersensitivity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm, PET-adapted regimen for untreated stage II bulky/III–IV classic Hodgkin lymphoma tests brentuximab vedotin + pembrolizumab with doxorubicin and dacarbazine (BvP+AD). Brentuximab vedotin: antibody–drug conjugate (anti‑CD30) delivering MMAE to CD30+ Hodgkin/Reed–Sternberg cells, causing microtubule disruption and apoptosis. Pembrolizumab: immune checkpoint inhibitor (humanized IgG4 mAb) blocking PD‑1/PD‑L1/PD‑L2 to restore antitumor T‑cell activity (cHL often overexpresses PD‑L1 via 9p24.1). Doxorubicin: anthracycline cytotoxic, DNA intercalation, topoisomerase II inhibition, ROS. Dacarbazine: triazene alkylating agent, DNA methylation/alkylation. Targets/pathways: CD30 on tumor cells, PD‑1 pathway on T cells, and DNA replication/repair in proliferating lymphoma cells.